Diseases [C] » Neoplasms
Description
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. MeSH
Hierarchy View
Subtype Terms (15)
Cysts
3 drugs (2 approved, 1 experimental)
Hamartoma
419 drugs (172 approved, 247 experimental)
Neoplasms by Histologic Type
65 drugs (44 approved, 21 experimental)
Neoplasms by Site
63 drugs (36 approved, 27 experimental)
Neoplasms, Experimental
2 drugs (1 approved, 1 experimental)
Neoplasms, Hormone-Dependent
4 drugs (3 approved, 1 experimental)
Neoplasms, Multiple Primary
3 drugs (2 approved, 1 experimental)
Neoplasms, Second Primary
28 drugs (25 approved, 3 experimental)
Neoplastic Processes
2 drugs (1 approved, 1 experimental)
Neoplastic Syndromes, Hereditary
14 drugs (12 approved, 2 experimental)
Paraneoplastic Syndromes
1 approved drug
Precancerous Conditions
131 drugs (94 approved, 37 experimental)
Phase 4 Indicated Drugs (155)
ferric carboxymaltose (Injectafer)
human papillomavirus 9-valent vaccine, recombinant (Gardasil 9)
human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant (Gardasil)
Phase 3 Indicated Drugs (214)
177lu-dota0-tyr3-octreotate (Dotatate)
18f-2-fluoro-2-deoxy-d-glucose fluorodeoxyglucose (FDG)
autologous hematopoietic stem cells
fam-trastuzumab deruxtecan-nxki (Enhertu)
ferric derisomaltose (Monoferric)
Phase 2 Indicated Drugs (539)
[18f]fluoropivalate ([18f]fluoro-2,2-dimethylpropionic acid)
2-(5-fluoro-pentyl)-2-methyl-malonic-acid
3,4-Methylenedioxymethamphetamine
4-demethyl-4-cholesteryloxycarbonylpenclomedine
allogeneic hematopoietic stem cells (Hemacord)
allogeneic natural killer cells
alvac melanoma multi-antigen therapeutic vaccine
antineoplaston AS2-1 (astugenal)
anti-ny eso-1 t cell receptor cd62l+ cells
anti-ny eso-1 t-cell receptor pbl
anti-p53 t-cell receptor-transduced peripheral blood lymphocytes
autologous cd34+ cells transduced withpsrs11.efs.il2rg.pre
autologous dendritic cells loaded with autologous tumor lysate
autologous ebv specific cytotoxic t lymphocytes
autologous natural killer cells
autologous tumor infiltrating lymphocytes
autologous umbilical cord blood
axicabtagene ciloleucel (Yescarta)
belantamab mafodotin (TECVAYLI)
brentuximab vedotin (adcetris)
Brexucabtagene autoleucel (Tecartus)
cd1c (bdca-1)+ / cd141 (bdca-3)+ mydc
DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine (Pediarix)
gadopenteate dimeglumine (magnevist)
human fecal microbiota (Reybota)
hyaluronidase (human recombinant) (Hylenex)
hydroxychloroquine (plaquenil)
interferon alpha-2a (roferon-a)
lisocabtagene maraleucel (Breyanzi)
lutetium (177Lu) vipivotide tetraxetan (Pluvicto)
modified vaccinia ankara-5t4 vaccine
multi-peptide cmv-modified vaccinia ankara vaccine
ny-eso-1 reactive tcr retroviral vector transduced autologous pbl
personalized neoantigen vaccine
Phase 1 Indicated Drugs (2112)
124i-iodo-azomycin galacto-pyranoside
4h11-28z/fil-12/efgrt+ genetically-modified t cells
5-aza-4'-thio-2'- deoxycytidine
68ga-1,4,7-triazacyclononane-n,n',n''-triacetic acid
7-t-butyldimethylsilyl-10-hydroxycamptothecin
adenovirus-mediated human interleukin-12
allogeneic adipose derived mesenchymal stem cell
anti-egfr immunoliposomes loaded with doxorubicin
anti-macrophage migration inhibitory factor antibody
anti-ny eso-1 tcr-transduced t cells
autologous ad her2 dendritic cells
autologous apd-l1 armored anti-cd22 car t cells
autologous cd19/cd22 chimeric antigen receptor t-cells
autologous, engineered t cells targeting tp53 r175h
autologous epstein-barr virus-transformed b-lymphoblastoid cell vaccine
autologous genetically modified afpc332 t cells
autologous mesenchymal stem cells
autologous ny-eso-1-specific cd8-positive t lymphocytes
av0113 dendritic cell cancer immune therapy
azurin-derived cell-penetrating peptide p28
bcl-2 antisense oligonucleotide
camptothecin-20-o-propionate hydrate
car-nk cells targeting nkg2d ligands
cmv pp65 peptide-loaded alpha-type-1 polarized dendritic cell vaccine
cngrc peptide-tnf alpha conjugate
colloidal gold-bound tumor necrosis factor
cytomegalovirus ie-1-specific cytotoxic t lymphocytes
cytomegalovirus pp65-specific cytotoxic t lymphocytes
dual-targeting cldn18.2 and pd-l1 car-t cells
egfrbi-armed autologous activated t cells
erwinia asparaginase (Erwinaze)
ga-68labeled f(ab') 2- trastuzumab
her2bi-armed activated t cells
human serum albumin/interferon alpha2b fusion protein
human single chain il-12 mrna-multiple dose
live attenuated influenza virus vaccine (Flumist)
mage-a4 tcr gene-modified t cells
mfe23 scfv-expressing autologous anti-cea mfez t lymphocytes
mirvetuximab soravtansine (Elahere)
modified vaccinia virus ankara vaccine expressing p53
multi-virus-specific cytotoxic t lymphocytes
mvf-her-2(628-647)-crl 1005 vaccine
neoantigen-expanded cell therapy.
nkg2dl-targetting chimeric antigen receptor-grafted gamma delta t cell
ny-eso-1(157-165) peptide-pulsed autologous dendritic cell vaccine
oncolytic virus cf33-expressing hnis/anti-pd-l1 antibody
procaspase activating compound-1
recombinant adenovirus-hifn-beta
recombinant fowlpox-b7.1 vaccine
recombinant fowlpox-cea(6d)/tricom vaccine
recombinant human il12/15-pdl1b oncolytic hsv-1 injection (vero cell))
recombinant vesicular stomatitis virus-expressing interferon-beta
ror1 car-specific autologous t-lymphocytes
sirna-transfected peripheral blood mononuclear cells apn401
tetra-o-methyl nordihydroguaiaretic acid
triethylenetetramine (trientine)
tumor associated antigen lymphocytes
tumor specific antigen induced cytotoxic lymphocyte
vaccinia-cea(6d)-tricom vaccine
y90 dota anti-cea monoclonal antibody m5a
young tumor infiltrating lymphocytes
Other Experimental Indicated Drugs (128)
ga-68-dota-toc (Ga-68-dota-toc)
gadofosveset trisodium (ablavar)
gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Primovist)
hepatitis a vaccine, inactivated (vaqta)
herv-e tcr transduced cd8+/cd34+ t cells in hlaa* 11:01 positive patients
Organization Involved with Phase 4 Indications (75)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Arbeitsgemeinschaft fur Internistische Onkologie (AIO)
Chinese Academy of Medical Sciences
Instituto Mexicano del Seguro Social
Institutul Clinic Fundeni, Bucarest, Romania
National Institute for Tuberculosis and Lung Diseases, Poland
Saint-Petersburg State Medical University
Shenzhen SiBiono GeneTech Co.,Ltd
Organization Involved with Phase 3 Indications (225)
Academic and Community Cancer Research United
Advanced Accelerator Applications
Albert Einstein Israelite Hospital
All India Institute of Medical Sciences
Arbeitsgemeinschaft Gynaekologische Onkologie Austria
Arbeitsgemeinschaft medikamentoese Tumortherapie
Badalona Hospital Germans Trias i Pujol
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
BioNumerik Pharmaceuticals, Inc.
Blokhin's Russian Cancer Research Center
Blueprint Medicines Corporation
Canadian Institutes of Health Research (CIHR)
Cancer and Leukemia Group B (CALGB)
Celilo Cancer Center at Mid-Columbia Medical Center
Children's Cancer and Leukaemia Group
Chinese Society of Lung Cancer
City of Hope National Medical Center
Clinical Research Technology S.r.l.
Danish Breast Cancer Cooperative Group
Dutch Health Care Insurance Board
Eastern Cooperative Oncology Group
Epidemiological and Clinical Research Information Network
European Organisation for Research and Treatment of Cancer
Guangzhou Bioseal Biotechnology Co., Ltd.
Herbert Irving Comprehensive Cancer Center
Huazhong University of Science and Technology
Icahn School of Medicine at Mount Sinai
Italian Association for Pediatric Hematology Oncology
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Krankenhaus der Barmherzigen Schwestern Linz
Medical Enterprises Europe B.V.
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute of Nursing Research (NINR)
National Institute on Aging (NIA)
National Institutes of Health (NIH)
Nordic Society for Gynaecologic Oncology
OncoQuest Pharmaceuticals Inc.
Oregon Health and Science University
People's Liberation Army of China
Radiation Therapy Oncology Group
St. Antonius Hospital, Nieuwegein
The Canadian Blood and Marrow Transplant Group
The Scientific and Technological Research Council of Turkey
Universidad Autonoma de Barcelona
University of Alabama, Birmingham
University of California, Irvine
University of California, Los Angeles
University of California, San Francisco
University of Rome Tor Vergata
University of Southern California
University of Southern Denmark
William Osler Health Service Brampton
Winnipeg Regional Health Authority
Xiamen Amoytop Biotech Co., Ltd.
ZonMw: The Netherlands Organisation for Health Research and Development
Organization Involved with Phase 2 Indications (600)
Acetylon Pharmaceuticals Incorporated
AIDS and Cancer Specimen Resource
Australasian Gastro-Intestinal Trials Group
Azienda Ospedaliera San Gerardo di Monza
Beijing InnoCare Pharma Tech Co., Ltd.
Big Ten Cancer Research Consortium
BioMed Valley Discoveries, Inc
British Columbia Cancer Agency
Canadian Society of Hematology
Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network
Cancer Biotherapy Research Group
Cancer Treatment Centers of America
Cantonal Hospital of St. Gallen
Case Western Reserve University
Catholic University of Sacred Heart, Rome
Centre Georges Francois Leclerc
Centre Hospitalier La Source, Orleans
Cheil General Hospital & Women's Healthcare Center
Chengdu Shi Endor Biological Engineering Technology Co., Ltd
Children's Medical Center Dallas
Ciusss de L'Est de l'Île de Montréal
Coastal Connecticut Research, LLC
Collaborative Ependymoma Research Network
Department of Radiation Oncology
Detroit Clinical Research Center
Developmental Therapeutics Consortium
East and North Hertfordshire NHS Trust
Elevation Pharmaceuticals, Inc.
Etablissement Français du Sang
Eucure (Beijing) Biopharma Co., Ltd
Excel Diagnostics and Nuclear Oncology Center
Federation Francophone de Cancerologie Digestive
Florida International University
Fundação de Amparo à Pesquisa do Estado de São Paulo
German Breast Group Forschungs GmbH
German Consortium for Translational Cancer Research
Global OB/GYN Centers of Florida
Gottfried Wilhelm Leibniz Universität Hannover
Greater Cincinnati OB/GYN, Inc.
Groupe Francophone des Myelodysplasies
Groupe Hospitalier Paris Saint Joseph
Grupo Espanol de Investigacion en Sarcomas
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Grupo Espanol de Tumores Neuroendocrinos (GETNE)
Grupo Espanol Multidisciplinario del Cancer Digestivo
Gruppo Italiano Trapianto di Midollo Osseo
Gruppo Oncologico del Nord-Ovest
Guangdong Association of Clinical Trials
Guangdong Pharmaceutical University
Guangdong Province Association Study of Thoracic Oncology
Hellenic Cooperative Oncology Group
Hoag Memorial Hospital Presbyterian
HonorHealth Research Institute
Hoosier Cancer Research Network
Hospital Santa Marcelina, Sao Paulo, Brasil
Hospital Universitario Niño Jesús
IGO Medical Group of San Diego
Immix Biopharma Australia Pty Ltd
Innovent Biologics (Suzhou) Co. Ltd.
Innsbruck - Tyrolean Working Group of Experimental Oncology
Institut de Cancérologie de la Loire (ICLN)
Institut de Cancerologie de l'Ouest Paul Papin
Institut de Cancérologie Lucien Neuwirth
Institut de Cancerologie Strasbourg Europe
Institut fuer Frauengesundheit
Instituto do Cancer do Estado de São Paulo
Instituto Nacional Canerologia
Instituto Nacional de Cancer, Brazil
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Istituto Clinico Humanitas - Rozzano (MI), Italy
Istituto Nazionale per lo Studio e la Cura dei Tumori
James Graham Brown Cancer Center
Jersey Shore University Medical Center
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Jiangsu Cancer Institute & Hospital
Jiangsu vcare pharmaceutical technology co., LTD
Kharkov Academy of Postgraduate Education
Korea Research Institute of Bioscience & Biotechnology
Lyndhurst Gynecologic Associates
Medical University of South Carolina
Memorial Sloan-Kettering Cancer Center
Methodist Cancer Center, Houston, Texas
Moorgreen Hospital, Southampton
Mount Vernon Clinical Research, LLC
Myeloproliferative Disorders Research Consoritum
Myeloproliferative Neoplasms Research Consortium
National Academy of Medical Sciences of Ukraine
National Cancer Institute, France
National Cancer Institute, Slovakia
National Center for Advancing Translational Science (NCATS)
National Center of Tumor Diseases (NCT) Dresden
National Cheng Kung University
National Comprehensive Cancer Network
Nationales Centrum fur Tumorerkrankungen
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Dental and Craniofacial Research (NIDCR)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of Neurological Disorders and Stroke (NINDS)
New Mexico Cancer Care Alliance
New York Presbyterian Hospital
North Eastern Germany Society of Gynaecologic Oncology
Northern California Research Corp
North Estonia Medical Centre Foundation
Norwegian University of Science and Technology
OB/GYN Specialists of the Palm Beaches
Odessa National Medical University
Organisation for Oncology and Translational Research
Paris 12 Val de Marne University
Pharmaceutical Research Associates, Inc. (PRA)
Physician Care Clinical Research LLC
Pierre and Marie Curie University
Radio Isotope Therapy of America
Robin Black OGNP, Costa Mesa California
Royal Marsden Hospital NHS Trust
Sarcoma Alliance for Research through Collaboration
Second Military Medical University
service Hématologie Séniors Hôpital Saint Louis
Shanghai Asclepius Meditec Inc.
Shanghai Cell Therapy Engineering Research Institute
Shanghai Cell Therapy Research Institute
Shanghai EpimAb Biotherapeutics Co., Ltd.
Shanghai Junshi Bioscience Co.,Ltd.
Shanghai Zhangjiang Biotechnology Limited Company
Shenzhen Geno-Immune Medical Institute
Shenzhen Hank Bioengineering Institute
ShiJiaZhuang Zhongxi Children Hospital
South Carolina Oncology Associates
Southern Europe New Drug Organization (SENDO)
South Texas Accelerated Research Therapeutics
SpringWorks Therapeutics, Inc.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Swiss Group for Clinical Cancer Research
Taizhou Hanzhong biomedical co. LTD
Taizhou Hospital of Zhejiang Province
Technical University of Dresden
The Christie NHS Foundation Trust
The First People's Hospital of Lianyungang
The Leukemia and Lymphoma Society
The Pacific Pediatric Neuro-Oncology Consortium
The University of Texas, Dallas
Tianjin Chase Sun Pharmaceutical Co., LTD
Tokyo Metropolitan Komagome Hospital
Universidad Autonoma de Madrid
Universidad Complutense de Madrid
Université catholique de Louvain
University of California, Davis
University of California, San Diego
University of Colorado, Denver
University of Electronic Science and Technology of China
University of Erlangen-Nuremberg
University of Illinois at Chicago
University of Naples Frederico II
University of Nice Sophia Antipolis
University of North Carolina at Chapel Hill
University of Technology, Sydney
University of Texas, San Antonio
Vall d'Hebron Institute of Research, Galatea Clinic
Virginia Commonwealth University
Vita-Salute University of Milano. Italy
Washington University in St. Louis
Organization Involved with Phase 1 Indications (520)
Aeon Therapeutics (Shanghai) Co., Ltd.
Alex's Lemonade Stand Foundation
Allife Medical Science and Technology Co., Ltd.
Anhui Province Cancer Hospital
Beijing Immunochina Medical Science & Technology Co., Ltd.
Beijing Konruns Pharmaceutical Co., Ltd.
Beijing Mabworks Biotech Co., Ltd.
Beijing Shenogen Biomedical Co., Ltd
Betta Pharmaceuticals Co.,Ltd.
Biotech Pharmaceutical Co., Ltd.
Bliss Biopharmaceutical Co., Ltd
California Institute for Biomedical Research
California Institute for Regenerative Medicine
Cancer Immunotherapy Trials Network
Center for Cancer Immune Therapy, Denmark
Centro Integral Oncológica Clara Campal
Centro Nacional de Investigaciones Oncológicas
Changchun Intellicrown Pharmaceutical Co. LTD
Children's National Medical Center
CTI Clinical Trial and Consulting Services
Cyclacel Pharmaceuticals, Inc.
Eastchester Center for Cancer Care
First People's Hospital of Hangzhou
Fountain Medical Development Co., Ltd.
Fujian Cosunter Pharmaceutical Co. Ltd
Fundacion CRIS de Investigación para Vencer el Cáncer
G&E Herbal Biotechnology Co., LTD
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Global Life Technologies Corp.
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Guangdong Xiangxue Precision Medical Technology Co., Ltd
Guangzhou FineImmune Biotechnology Co., LTD.
Guangzhou Gloria Biosciences Co., Ltd.
Guangzhou Xiangxue Pharmaceutical Co., Ltd
GU Russian Oncology Research Centre
GZA Ziekenhuizen Campus Sint-Augustinus
Handok Pharmaceuticals Co., Ltd.
Hangzhou Neoantigen Therapeutics Co., Ltd.
Harris County Hospital District
Hebei Senlang Biotechnology Inc., Ltd.
Hemay Pharmaceutical PTY. LTD.
Henan Provincal People's Hospital
Holy Stone Healthcare Co., Ltd
Hospital Universitario Austral
Hubei Biological Medicine Industrial Technology Institute Co., Ltd.
ImmunoVaccine Technologies, Inc.
Infinity Pharmaceuticals, Inc.
Innovative Cellular Therapeutics Co., Ltd.
Instituto de Medicina Regenerativa
Istituto Oncologico Veneto IRCCS
Jacobio Pharmaceuticals Co., Ltd.
James B. and Lois R. Archer Charitable Foundation
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Jilin Provincial Tumor Hospital
Jingchu University of Technology
Lawrence Livermore National Laboratory
Lipomedix Pharmaceuticals Inc.
Lishui Country People's Hospital
Livzon Pharmaceutical Group Inc.
Ludwig Institute for Cancer Research
Lyvgen Biopharma Holdings Limited
Marino Biotechnology Co., Ltd.
Minghui Pharmaceutical Pty Ltd
Nanjing Bangnuo Biotechnology Co. Ltd
Nanjing Sanhome Pharmaceutical, Co., Ltd.
National Center for Complementary and Integrative Health (NCCIH)
National Hospital Organisation Kyushu Cancer Centre
National Hospital Organisation Nagoya Medical Centre
National Institute for Health Research, United Kingdom
National University of Ireland
National University of Singapore
NatureWise Biotech & Medicals Corporation
NeuroEndocrine Tumor Research Foundation (NETRF)
Nizam's Institute of Medical Sciences, Hyderabad, India
North Shore Hospital, New Zealand
Nventa Biopharmaceuticals Corporation
Ospedale S. Giovanni Bellinzona
Pediatric Brain Tumor Consortium
Pediatric Oncology Experimental Therapeutics Investigation Consortium
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Pionyr Immunotherapeutics Inc.
RM/ICR Biomedical Research Centre
Shanghai bokang bioengineering co., LTD
Shanghai De Novo Pharmatech Co., Ltd.
Shanghai University of Traditional Chinese Medicine
Shanghai YingLi Pharmaceutical Co. Ltd.
Shenzhen Ionova Life Sciences Co., Ltd.
Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd
SignalChem Lifesciences Corporation
SignalRX Pharmaceuticals, Inc.
Simcere Pharmaceutical Co., Ltd
South Plains Oncology Consortium
South Texas Oncology and Hematology
Statistical Revelations Pty Ltd
Sunshine Lake Pharma Co., Ltd.
Sydney Children's Hospitals Network
Taipei Veteran General hospital
Taivex Therapeutics Corporation
Tapestry Pharmaceuticals, Inc.
The Beatson West of Scotland Cancer Centre
The Cancer Institute Hospital of JFCR
The First People's Hospital of Yunan Province
The Lymphoma Academic Research Organisation
Translational Drug Development
Traslational Cancer Drugs Pharma, SL
Triphase Research and Development Corporation
Tvardi Therapeutics, Incorporated
University of California, Berkeley
University of Medicine and Dentistry of New Jersey
University of Science and Technology of China
University of Texas, Galveston
University of Western Australia
Wuhan Bio-Raid Biotechnology Co, Ltd. China
Xiangxue Life Science Research Center
Yooyoung Pharmaceutical Co.,Ltd.
Organization Involved with Other Experimental Indications (36)
American Society of Clinical Oncology
Amrita Institute of Medical Sciences
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.